Novavax Vaccine Progress Pipeline | Novavax
Novavax continues to optimize preclinical candidates, including a new approach to H5N1 bird flu vaccination. In addition, we are seeking to expand our core technology to new targets and novel applications including mucosal vaccination and high-density nanoparticles.
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine …
Oct 9, 2024 · The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine.
Home | Novavax, Inc.
We are a biotechnology company committed to addressing serious infectious diseases globally through the discovery and development of innovative vaccines.
Novavax Continues to Partner with the U.S. FDA on Review of …
Aug 22, 2024 · Novavax and the U.S. Food and Drug Administration (FDA) are working together productively as the U.S. FDA continues its review of data in consideration of an Emergency Use Authorization (EUA) of Novavax’s 2024-2025 formula COVID-19 vaccine (NVX-CoV2705).
Explore Our Vaccine Research & Technology | Novavax
We are committed to delivering novel products that leverage cutting edge recombinant protein nanoparticles to protect against a broad range of infectious diseases. Learn more. Our pipeline—creating tomorrow's vaccine today. Publications. Learn about Novavax's vaccine research and technology.
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza ...
May 9, 2023 · With Novavax's unique recombinant nanoparticle technology, the non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus, while Novavax's Matrix-M adjuvant enhances and broadens the immune response.
Update on Novavax's COVID-19-Influenza Combination and Stand …
Oct 16, 2024 · The Company's portfolio includes its COVID-19 vaccine and its pipeline includes its CIC and tNIV vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine.
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine …
Sep 8, 2021 · Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission.
Novavax Reports Fourth Quarter and Full Year 2023 Financial …
Feb 29, 2024 · Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion. Accelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza Combination vaccine trial in second half 2024 and potential 2026 launch. Rescaled global footprint with 30% total headcount reduction as compared to Q1 2023.
Malaria Vaccine: Collaborating for a Malaria-Free Future - Novavax
The R21/Matrix-M™ malaria vaccine was developed by the University of Oxford and Serum Institute of India and contains the R21 antigen Novavax's Matrix-M adjuvant.